Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals

Launched by PHARMACIA AND UPJOHN · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • HIV positivity confirmed by Western blot.
• • CD4 count of 100 - 500 cells/mm3 on a morning draw within 3 weeks prior to study entry.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following symptoms and conditions are excluded:
• • Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of the cervix, or nondisseminated Kaposi's sarcoma.
• • Hemophilia or other clotting disorders.
• • Major organ allograft.
• • Significant cardiac, hepatic, renal, or CNS disease.
• Prior Medication:
• Excluded:
• • Antiretroviral agents within 2 months prior to study entry.
• • Known anti-HIV medication within 60 days prior to study entry.
• • Prior immunomodulators (e.g., systemic steroids, interferons, or interleukins) or other chemotherapy.
• Prior Treatment:
• Excluded:
• • Prior radiation therapy. Active substance abuse.